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Objectives  24 
To explore the risk factors for, and clinical outcomes in men-who-have-sex-with-men (MSM) 25 
prescribed HIV post-exposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics 26 
(SHCs) in England. 27 
Methods 28 
National sexually transmitted infection (STI) surveillance data were extracted from the genitourinary 29 
medicine clinic activity dataset (GUMCADv2) for 2011-2014.   Quarterly and annual trends in the 30 
number of episodes where PEPSE was prescribed were analysed by gender and sexual risk.  Risk factors 31 
associated with being prescribed PEPSE among MSM attendees were explored using univariable and 32 
multivariable logistic regression. Subsequent HIV acquisition from 4 months after initiating PEPSE was 33 
assessed using multivariable Cox proportional hazards models, stratified by clinical risk profiles. 34 
Results 35 
During 2011-2014, there were 24,004 episodes where PEPSE was prescribed at SHCs, of which 69% 36 
were to MSM. The number of episodes where PEPSE was prescribed to MSM increased from 2,383 in 37 
2011 to 5,944 in 2014, and from 1,384 to 2,226 for heterosexual men and women. 15% of MSM 38 
attendees received two or more courses of PEPSE. Compared to MSM attendees not prescribed PEPSE, 39 
MSM prescribed PEPSE were significantly more likely to have been diagnosed with a bacterial STI in 40 
the previous 12 months [aOR(95% CI) – gonorrhoea: 11.6(10.5-12.8); chlamydia: 5.02(4.46-5.67); 41 
syphilis: 2.25(1.73-2.93)], and were more likely to subsequently acquire HIV [aHR(95%CI) - single 42 
PEPSE course: 2.54(2.19-2.96); two or more PEPSE courses: aHR(95%CI) 4.80(3.69-6.25)].  The 43 
probability of HIV diagnosis was highest in MSM prescribed PEPSE who had also been diagnosed with 44 




MSM prescribed PEPSE are at high risk of subsequent HIV acquisition and our data show further risk 47 
stratification by clinical and PEPSE prescribing history is possible, which might inform clinical practice 48 
and HIV prevention initiatives in MSM.  49 
Abstract word count: 284  50 
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KEY MESSAGES 51 
 PEPSE is a method to prevent HIV infection, but there are limited data on the surveillance and 52 
epidemiology of PEPSE prescribing at a national level. 53 
 During 2011-2014, the number of episodes where PEPSE was prescribed increased markedly in 54 
MSM compared to heterosexual men and women. 55 
 MSM prescribed PEPSE, and in particular those prescribed two or more courses, are at high risk of 56 
subsequent HIV infection.  57 
 These data might support clinical risk assessment decisions, including about the need for PrEP as 58 
part of a multi-component HIV prevention package. 59 




Post-exposure prophylaxis following sexual exposure (PEPSE) is a potential method to prevent HIV 62 
infection. Current UK guidelines recommend that PEPSE, consisting of a 28-day course of antiretroviral 63 
therapy (Truvada (emtricitabine/tenofovir) and raltegravir) is offered to individuals who present 64 
within 72 hours of a defined risk exposure such as receptive unprotected anal intercourse (UAI) with 65 
a partner of unknown HIV status and from a known risk-group.[1] An HIV test is performed at baseline 66 
to rule out undiagnosed HIV infection, and a follow-up HIV test is performed 8-12 weeks post-67 
exposure.[1] 68 
Prospective randomised controlled trials (RCTs) to measure the efficacy of PEPSE are not ethically 69 
justifiable.[1] Consequently, there is a lack of evidence on the clinical effectiveness of PEPSE, and 70 
current UK guidelines draw on observational studies, animal studies, and an understanding of the 71 
biology of HIV transmission.[1] The guidelines also state that other HIV prevention strategies should 72 
be prioritised, such that PEPSE is considered only where these have failed.[1] 73 
In the UK, men-who-have-sex-with-men (MSM) are the population most at-risk of acquiring HIV, 74 
accounting for over half (55%; 3,360) of all new HIV diagnoses reported in 2014. The number of HIV 75 
diagnoses annually in MSM has shown a steadily rising trend over the past decade, which can be 76 
explained by increases in HIV testing as well as high levels of on-going HIV transmission.[2,3]  77 
We analysed PEPSE prescribing in sexual health clinics (SHCs) in England using national surveillance 78 
data to understand better the role of PEPSE in HIV prevention, including any future pre-exposure 79 
prophylaxis (PrEP) policy, and to inform clinical decision making and resource allocation.  We have 80 
described recent trends in PEPSE prescribing in SHCs and explored the risk factors for, and subsequent 81 
HIV diagnoses in MSM attendees prescribed PEPSE. 82 




Data source 85 
Data were extracted from the genitourinary medicine clinic activity dataset (GUMCADv2), a patient-86 
level dataset containing information on sexually transmitted infection (STI) diagnoses and services 87 
provided by all genitourinary medicine (GUM) and integrated GUM/sexual & reproductive health 88 
services in England (referred to as SHCs).  Clinical data are reported using national Sexual Health and 89 
HIV Activity Property Type (SHHAPT) codes and each attendance includes information on patient 90 
demographics (gender, age, sexual orientation, self-reported ethnicity and country of birth) and area 91 
of residence.[4] The national SHHAPT code for PEPSE (“PEPS”) was introduced on 1st January 2011. 92 
Attendances by the same individual can be linked within SHCs (but not between clinics), enabling the 93 
identification of repeat visits and subsequent clinical diagnoses.[4]  94 
Study population 95 
All HIV-negative (defined as no prior HIV diagnosis-related SHHAPT code) attendees aged 16 years or 96 
over attending SHCs in England during 2011-2014 were included in the study.  Individuals prescribed 97 
PEPSE were those who had a clinical record with the appropriate SHHAPT code. 126 episodes 98 
(accounting for 78 attendees) of PEPSE were recorded after a HIV diagnosis-related SHHAPT code.  99 
These were assumed to be clinical coding errors and were excluded from further analysis.  MSM were 100 
defined as men who had reported sex with another man (i.e. their sexual orientation was self-reported 101 
as homosexual or bisexual) at least once during their clinic attendance history.  102 
Data analysis 103 
Trends in the number of episodes where PEPSE was prescribed were assessed using quarterly data 104 
between 2011 and 2014.  The Kolmogorov-Smirnov test was used to compare the overall increase by 105 
year in the number of episodes where PEPSE was prescribed by gender/sexual risk.  We used the 106 
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British National Formulary (BNF) price for a 28-day course of PEPSE (£772 in March 2016) to estimate 107 
the annual drug cost based on the number of episodes where PEPSE was prescribed.  108 
Risk factors for being prescribed PEPSE were identified in the population of HIV-negative MSM 109 
attendees who were allocated to two groups based on their attendance history during 2011-2014: (i) 110 
those prescribed PEPSE and (ii) those not prescribed PEPSE. Demographic characteristics (age, 111 
ethnicity, country of birth and clinic location) were explored using the first recorded episode where 112 
PEPSE was prescribed or the first attendance for those not prescribed PEPSE. Ethnicity was defined by 113 
patient self-report and categorised based on the national Census codes.  Country of birth was reported 114 
as International Organisation for Standardisation codes and categorised according to Office for 115 
National Statistics (UK) regions.  We investigated the proportion of MSM diagnosed with an acute 116 
bacterial STI (chlamydia, gonorrhoea or infectious syphilis) in the year prior to and at their first 117 
recorded PEPSE episode or first attendance.  Univariate and multivariable logistic regression were 118 
used to investigate demographic and clinical risk factors associated with PEPSE.  Records with missing 119 
data on any of the variables were excluded (23,559 attendees out of a total of 253,496). 120 
We used the Kaplan-Meier method to estimate the proportion of HIV-negative MSM attendees with 121 
a subsequent diagnosis code.  To exclude incident HIV infections undiagnosed at the time of the PEPSE 122 
prescription, and to discount PEPSE failure, time at risk for HIV began four months after starting the 123 
most recent PEPSE course. This was based on the UK guidelines for PEPSE at the time (2011) which 124 
recommended follow-up HIV testing twelve weeks post-completion of the PEPSE course.[5] Those not 125 
prescribed PEPSE were considered to be at risk from four months after their first attendance. MSM 126 
were censored at their HIV diagnosis or at the end of the follow-up period (30th September 2015).  127 
MSM whose first attendance was less than 4 months before the end of the follow-up period were 128 
excluded.  Where no HIV code was reported, we assumed that MSM remained HIV negative regardless 129 
of whether they returned for a subsequent HIV test.  Log rank tests were used to compare survival 130 
curves by the number of PEPSE courses prescribed and by the following risk profiles:  131 
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(i) No PEPSE courses and no bacterial STI in the past 12 months 132 
(ii) At least one PEPSE course and no bacterial STI in the past 12 months 133 
(iii) No PEPSE courses and a bacterial STI in the past 12 months 134 
(iv) At least one PEPSE course and a bacterial STI in the past 12 months 135 
Cox proportional hazards models were used to estimate hazard ratios and to adjust for confounders 136 
(age, ethnicity, region of birth and clinic location). Records with missing data on any of the variables 137 
were excluded from the modelling (23,493 attendees out of a total of 252,257). 138 
A sensitivity analysis was conducted to explore a more conservative censoring method; MSM were 139 
censored at their HIV diagnosis or the last HIV test.  MSM with no subsequent HIV test were excluded 140 
from this sensitivity model resulting in a reduced study population of 88,431 (excluding 6,332 with 141 





During 2011-2014, there were 24,004 episodes where PEPSE was prescribed at SHCs in England: 145 
16,422 (68%) were prescribed to MSM, 3,333 (14%) were prescribed to heterosexual men and 3,963 146 
(17%) were prescribed to women. 147 
The number of episodes where PEPSE was prescribed to MSM increased from 370 in the first calendar 148 
quarter (Q1) of 2011 to 1,632 in Q4 of 2014, with the steepest increase between Q2 and Q3 of 2011 149 
(70%).  The overall increase in the number of episodes where PEPSE was prescribed by year was 150 
significantly greater for MSM (150%; 2,382 to 5,944) compared to heterosexual men (62%; 625 to 151 
1,104) and women (60%; 759 to 1,212), (p<0.001, Kolmogorov-Smirnov test) (figure 1). The estimated 152 
drug cost of PEPSE prescribing in 2014 was over £6 million per year, with £4.5 million attributable to 153 
MSM.  There was a year-on-year increase in the proportion of all MSM attendees at SHCs who were 154 
prescribed PEPSE (2.01% in 2011 to 3.82% in 2014) (online supplementary table).  155 
During 2011-2014, 13,453 MSM attendees were prescribed PEPSE.   15% (1,981) were prescribed more 156 
than one course; of these, 71% (1,412) were prescribed 2 courses of PEPSE and 29% (569) 3 or more 157 
courses (maximum 13 courses). Among MSM prescribed more than one course, 60% (1,194/1,981) 158 
received a second course less than 6 months after the first course. The proportion of MSM attendees 159 
prescribed multiple courses (2 or more) within a given calendar year did not change; 12.4% 160 
(254/2,055) in 2011 compared to 9.9% (520/5,282) in 2014. 161 
Of MSM attendees prescribed PEPSE, 45% (6,051/13,447) were aged 25-34 years, 80% 162 
(10,171/12,784) were white and 63% (7,975/12,679) were born in the UK. Two thirds (67%; 9,033) 163 
were prescribed PEPSE at a London-based service. 54% (7,229) had a prior attendance recorded at the 164 
same SHC since 2008, of which 83% (5,960) had attended at least once in the previous year.  This was 165 
higher than the prior attendance rate for MSM not prescribed PEPSE; 18% (44,004/240,043) had a 166 
prior attendance, of which 42% (18,506) had attended at least once in the previous year.  5.4% (725) 167 
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of MSM prescribed PEPSE were diagnosed with at least one acute bacterial STI at the same attendance 168 
as the PEPSE prescription; 3.3% (443) were diagnosed with gonorrhoea, 2.1% (287) with chlamydia 169 
and <1% (57) with infectious syphilis. 10.8% (1,446) of all MSM prescribed PEPSE had been diagnosed 170 
with at least one acute bacterial STI in the previous year; 7.2% (974) were diagnosed with gonorrhoea, 171 
4.8% (648) with chlamydia and <1% (112) with infectious syphilis.  Among all MSM not prescribed 172 
PEPSE, 11.8% (28,455) had at least one acute bacterial STI at their first attendance; 6.9% (16,642) were 173 
diagnosed with gonorrhoea, 5.1% (12,238) with chlamydia and 1% (2,415) with infectious syphilis.  174 
Only 1.1% (2,574) of all MSM not prescribed PEPSE had been previously diagnosed with at least one 175 
acute bacterial STI. 176 
In the multivariable analysis, MSM prescribed PEPSE were more likely to be aged 25-44 years, be born 177 
outside of the UK, particularly sub-Saharan Africa [aOR(95% CI): 1.27(1.13-1.43)] or the Caribbean 178 
[aOR(95% CI): 1.36(1.08-1.72) (table 1), be of mixed, [aOR(95% CI):1.29(1.17-1.41)] or black other 179 
(non-Caribbean/non-African) ethnicity [aOR(95% CI)1.23(1.01-1.51)] compared to White ethnicity, 180 
and to have attended a SHC in London [aOR(95% CI):0.56(0.53-0.58) for non-London versus London 181 
SHCs].  MSM prescribed PEPSE were less likely to be diagnosed with an acute bacterial STI at the same 182 
attendance [aOR(95% CI) – gonorrhoea: 0.45(0.40-0.50); chlamydia: 0.44(0.39-0.50); syphilis: 183 
0.51(0.39-0.67)] but were more likely to have had a bacterial STI in the 12 months prior to the PEPSE 184 
prescription [aOR(95% CI) – gonorrhoea: 11.6(10.5-12.8); chlamydia: 5.02(4.46-5.67); syphilis: 185 
2.25(1.73-2.93)].  The positive association between a previous bacterial STI diagnosis and PEPSE 186 








Table 1: Independent risk factors associated with the first reported episode where PEPSE was 193 














Age group (years)           
<20 13,277 507 (3.8%) 0.57 (0.52-0.62) 0.76 (0.69-0.84) <0.001 
20-24 46,204 2,164 (4.7%) 0.70 (0.67-0.74) 0.81 (0.77-0.86) <0.001 
25-34 84,162 5,491 (6.5%) 1 1   
35-44 46,494 2,869 (6.2%) 0.94 (0.90-0.99) 0.96 (0.91-1.00) 0.066 
≥45 39,800 1,258 (3.2%) 0.47 (0.44-0.50) 0.53 (0.50-0.56) <0.001 
            
Ethnic group      
White 194,691 9,812 (5.0%) 1 1  
Asian 10,707  695 (6.5%) 1.31 (1.21-1.42) 1.03 (0.95-1.13) 0.456 
Black Caribbean 3,427 217 (6.3%) 1.27 (1.11-1.46) 1.01 (0.86-1.18) 0.944 
Black African 3,166 221 (7.0%) 1.41 (1.23-1.62) 0.99 (0.85-1.17) 0.939 
Black other 1,467 117 (8.0%) 1.63 (1.35-1.97) 1.23 (1.01-1.51) 0.039 
Mixed 7,621 585 (7.7%) 1.57 (1.44-1.71) 1.29 (1.17-1.41) <0.001 
Other 8,858 642 (7.3%) 1.47 (1.36-1.60) 1.08 (0.99-1.19) 0.089 
  
   
 
Region of Birth           
UK 166,832 7,722 (4.6%) 1 1   
Europe (non-UK) 30,039 2,084 (6.9%) 1.54 (1.46-1.62) 1.12 (1.06-1.18) <0.001 
Caribbean 1,244 102 (8.2%) 1.84 (1.50-2.26) 1.36 (1.08-1.72) 0.009 
Sub-Saharan Africa 5,756 439 (7.6%) 1.70 (1.54-1.88) 1.27 (1.13-1.43) <0.001 
Other 26,066 1,942 (7.5%) 1.66 (1.57-1.75) 1.18 (1.10-1.25) <0.001 
            
 
SHC location 
     
London 115,959 8,185 (7.1%) 1 1  




   
 
Coincident gonorrhoea           
No 214,366 11,889 (5.6%) 1 1   
Yes 15,571 400 (2.6%) 0.45 (0.41-0.50) 0.45 (0.40-0.50) <0.001 
            
Coincident chlamydia      
No 218,498 12,027 (5.5%) 1 1  
Yes 11,439 262 (2.3%) 0.40 (0.36-0.46) 0.44 (0.39-0.50) <0.001 
  
   
 
Coincident syphilis           
No 227,685 12,233 (5.4%) 1 1   
Yes 2,252 56 (2.5%) 0.45 (0.34-0.59) 0.51 (0.39-0.67) <0.001 
            
History of gonorrhoea      
No 227,971 11,369 (5.0%) 1 1  
Yes 1,966 920 (46.8%) 16.8 (15.3-18.4) 11.6 (10.5-12.8) <0.001 
 
    
 
History of chlamydia           
No 228,106 11,695 (5.1%) 1 1   
Yes 1,831 594 (32.4%) 8.89 (8.04-9.82) 5.02 (4.46-5.67) <0.001 
            
History of syphilis      
No 229,444 12,188 (5.3%) 1 1  
Yes 493 101 (20.5%) 4.59 (3.69-5.72) 2.25 (1.73-2.93) <0.001 
            
OR, Odds Ratio; CI, confidence interval. Unadjusted and adjusted odds ratios calculated using logistic 195 
regression.  Adjusted for all variables listed in the table only. Infectious syphilis includes primary, 196 
secondary and early latent diagnoses.  Mixed ethnicity includes white and black Caribbean, white and 197 




Overall, 255 (1.9%) MSM attendees prescribed PEPSE and 1,817 (0.8%) MSM not prescribed PEPSE 200 
were subsequently diagnosed with HIV with estimated HIV diagnosis rates of 9.7 per 1000 person-201 
years (95%CI 8.6-11.0) and 3.0 per 1000 person years (95% CI 2.8-3.1), respectively.  The HIV diagnosis 202 
rate was considerably higher among MSM attendees who were prescribed two or more courses of 203 
PEPSE (18.2 per 1000 person-years (95% CI 14.1-23.6) compared to those prescribed one course (8.5 204 
per 1000 person-years (95% CI 7.4-9.8) (figure 2a and table 2a).  In the sensitivity analysis, MSM 205 
prescribed PEPSE had a HIV diagnosis rate of 38.5 per 1000 person-years (95% CI 34.0-43.5) compared 206 
to 13.6 per 1000 person-years (95% CI 12.9-14.2) among those not prescribed PEPSE.  The HIV 207 
diagnosis rate for MSM prescribed 2 or more courses of PEPSE was 50.8 per 1000 person-years (95% 208 
CI 39.1-66.0) compared to 35.9 per 1000 person-years (95% CI 31.2-41.4) for MSM prescribed one 209 
course.  This association was only weakly significant reflective of the smaller study population. 210 
The probability of a HIV diagnosis varied according to risk profiles; MSM prescribed PEPSE and with a 211 
bacterial STI in the past 12 months had a considerably higher rate of HIV diagnosis (24.1 per 1000 212 
person-years (95%CI 19.1-30.5) when compared to all other risk profiling groups (figure 2b).  The HIV 213 
diagnosis rate was 6-fold higher compared to those with the lowest risk profile (table 2b).  In the 214 
sensitivity analysis, the same general trends were observed (data not shown). 215 
 216 
  217 
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Table 2: Unadjusted and adjusted Hazard ratios for subsequent HIV infection risk in MSM, 2011-2014 218 
a) by the number of PEPSE courses 219 
*Total person-years at risk to the nearest whole number 220 
**Analysis adjusted for age, ethnic group, world region of birth and SHC location. HR, Hazard ratio; 221 
CI, confidence interval. Adjusted and unadjusted hazard ratios calculated using Cox Proportional 222 
Hazards model 223 




















Number of PEPSE courses       
None 216,581 552,957 1,733 1 1  
Single 10,352 20,558 189 2.72 (2.34-3.16) 2.54 (2.19-
2.96) 
<0.001 



















Risk Strata       
No PEPSE, No STI 214,192 543135 1,637 1 1  
PEPSE, No STI 10,569 20847 178 2.62 (2.25-
3.06) 
2.44 (2.09-2.86) <0.001 
No PEPSE, STI 2,389 9822 96 3.83 (3.11-
4.70) 
3.98 (3.24-4.90) <0.001 
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*Total person-years at risk to the nearest whole number 225 
 *Analysis adjusted for age, ethnic group, world region of birth and SHC location. HR, Hazard ratio; CI, 226 
confidence interval. Adjusted and unadjusted hazard ratios calculated using Cox Proportional Hazards 227 
model  228 
  229 
PEPSE, STI 1,614 2679 69 7.58 (5.95-
9.64) 




Main findings 231 
The number of episodes where PEPSE was prescribed to MSM increased substantially and more 232 
rapidly than for heterosexual men and women. 13,453 (4.5% overall) MSM attendees at SHCs in 233 
England during 2011-2014 were prescribed at least one episode of PEPSE and repeat prescribing was 234 
common (15% were prescribed two or more courses).  MSM attendees diagnosed with a bacterial STI 235 
in the past 12 months were between 2 and 12-times more likely to be prescribed PEPSE compared to 236 
those without a previous STI infection.  Of note, MSM prescribed PEPSE, and in particular those 237 
prescribed two or more courses of PEPSE, were at high risk of subsequent HIV acquisition. 238 
Strengths and Limitations 239 
The strength of this study lies in the interrogation of national surveillance data with mandatory 240 
reporting from all specialist SHCs in England. The scale and detail of data using standardised reporting 241 
definitions are unprecedented and this study therefore provides a unique overview of PEPSE 242 
prescribing to inform clinical decision making and resource allocation. 243 
This study has several limitations.  First, although GUMCADv2 provides patient-level data it is not 244 
possible to track patients between clinics. In a pilot study, 15% of MSM reported ever attending 245 
another SHC, [6] and this may be more common in urban settings like London[7], which might lead to 246 
underestimation of HIV acquisition and repeat PEPSE prescribing in our study.   Second, we have 247 
assumed that MSM were HIV negative until the end of follow-up time in the Kaplan-Meier analysis, 248 
unless they had a new HIV diagnosis, which might also underestimate HIV acquisition.  However, the 249 
results of the sensitivity analysis, in which a more conservative approach was taken, were in 250 
accordance with the original model.  Third, reporting of PEPSE prescribing was introduced in 2011 and 251 
there was an initial and expected lag phase in reporting such that overall PEPSE prescribing may be 252 
underestimated in our analysis during the early stages of 2011. However, we are confident that PEPSE 253 
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coding was fully integrated into clinical practice by mid-2011, as implied by the fact that the trend 254 
lines for heterosexual males and females remain relatively stable after this time (figure 1) and thus 255 
the impact is likely to be minimal.  Fourth, sexual behaviour is strongly associated with both PEPSE use 256 
and HIV acquisition and the absence of these data limited our ability to interpret associations in our 257 
analyses.  We used data on previous STI acquisition as a proxy measure for high-risk behaviour as this 258 
is a known predictor of HIV infection.[8] 259 
Interpretation 260 
We found a strong association between PEPSE use and a previous bacterial STI infection which 261 
suggests that MSM prescribed PEPSE represent a group with higher risk behaviours, as has been 262 
reported elsewhere. [9,10]  The fact that MSM prescribed PEPSE were less likely to present with a 263 
bacterial STI at their attendance for PEPSE was expected, since PEPSE is provided within 72 hours of a 264 
sexual risk exposure when any STI is not likely to be detectable.  MSM prescribed PEPSE were at high-265 
risk of HIV acquisition and the strong association between the number of PEPSE courses prescribed 266 
and the rate of HIV diagnosis suggests that PEPSE is a marker of on-going risk behaviour.  Several 267 
observational studies have reported HIV seroconversion after receiving PEPSE due to ongoing risk 268 
behaviour and re-exposure to HIV.[11-13] PEPSE use among a community cohort of MSM in Australia 269 
did not lead to a reduction in risk behaviour and those prescribed PEPSE had a higher rate of 270 
subsequent HIV seroconversion.[11] A retrospective review of MSM attending an urban health centre 271 
in Boston for PEPSE found no association between repeat PEPSE use and HIV infection risk compared 272 
with single PEPSE use, which differs from our results.  However, the number of participants was 273 
smaller. [13] The association between a previous bacterial STI infection and HIV acquisition has been 274 
found elsewhere [14-16] and our study identified a particular sub-set of MSM prescribed PEPSE and 275 





In recent years, PEPSE use as an HIV prevention measure among MSM has increased and there is no 279 
indication that this will change.  The overall cost is high (£4.5 million in MSM) despite the weak 280 
evidence base for its clinical effectiveness.[5] We have shown that PEPSE is a strong marker of 281 
subsequent risk behaviour and HIV acquisition among MSM attending SHCs and thus accessing a high 282 
standard of preventative care.  In our analysis, 15% of MSM were prescribed PEPSE more than once 283 
at the same clinic and exhibited a 5-fold increased risk of acquiring HIV infection despite receiving 284 
counselling and advice on risk reduction strategies.  MSM prescribed PEPSE, and especially  those 285 
returning for repeat PEPSE would benefit from more intensive risk reduction interventions.[1]  286 
Furthermore, national trends show a steadily increasing number of HIV diagnoses in MSM, and 287 
evidence from community-based surveys of sexual behaviour in MSM suggest that there is a need to 288 
enhance the existing HIV prevention package. Community based surveys have shown increases in UAI 289 
with casual partners,[16,17] self-reported STIs,[16] and UAI with a main partner of a different HIV 290 
status.[18] 291 
A number of well-designed RCTs have demonstrated the very strong effectiveness of pre-exposure 292 
prophylaxis (PrEP) for preventing HIV infection among gay, bisexual and other MSM,[19,20] and 293 
support the inclusion of PrEP within a multicomponent HIV prevention package for MSM at risk, 294 
incorporating behavioural, structural and biomedical approaches based on robust scientific 295 
evidence.[21] In the deferred arm of the PROUD study (i.e. those who received PrEP after a deferral 296 
period of 1 year), PEPSE prescribing was common but HIV incidence was also very high.[19]  Any HIV-297 
PrEP programme is likely to be delivered through SHCs and reduce the number of MSM prescribed 298 
PEPSE and their subsequent risk of HIV acquisition.  Furthermore, survey data suggest that MSM 299 
prescribed PEPSE are more likely to consider PrEP compared to those with no experience of PEPSE.[22]  300 
Of course, the value of PrEP is closely related to HIV incidence in various sub-groups of the high-risk 301 
population and the cost savings that can be achieved, which is beyond the scope of this study. 302 
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Overall, we found that the number of episodes where PEPSE was prescribed has increased markedly 303 
in MSM, and that MSM attendees prescribed PEPSE are at sustained increased risk of acquiring HIV. 304 
This information is directly actionable, by supporting MSM who have been prescribed PEPSE to reduce 305 
sexual behavioural risk, and these MSM may be an appropriate group to target with PrEP.  Biomedical 306 
interventions, like PrEP, in combination with other HIV prevention strategies including condom 307 
promotion, behavioural change and increased HIV testing may be beneficial for MSM that present for 308 
PEPSE, particularly those who have been previously diagnosed with a bacterial STI.  309 
 310 
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FIGURE LEGENDS 404 
 405 
Figure 1: Trends in the number of episodes where PEPSE was prescribed by gender & sexual risk, 406 
England, 2011-2014 407 
 408 
Figure 2: Kaplan-Meier curves showing time to HIV diagnosis among MSM attendees, 2011-2014: 409 
a) by the number of PEPSE courses prescribed 410 
b) by clinical risk profiles 411 
 412 
